Source: Eur Respir J 2015; 45: 260-262
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Roche Nicolas, Jebrak Gilles, Caillaud Denis, Deslée Gaetan, Brinchault Graziella, Chanez Pascal, Court-Fortune Isabelle, Escamilla Roger, Nesme-Meyer Pascale, Pinet Christophe, Carré Philippe, Paillasseur Jean-Louis, Perez Thierry, Burgel Pierre-Régis. Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment. Eur Respir J 2015; 45: 260-262

Member's Comments

No comment yet.

Related content which might interest you: Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018 First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007 Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007 Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003 Initial anticholinergic therapy COPD Source: Eur Respir J 2006; 28: Suppl. 50, 29s Year: 2006 Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001 Survey of dyspnoea in COPD patients on medication and preemptive use of a short-acting β-2 agonist Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 The anti-tussive effects of an inhaled LABA are maintained after chronic treatment Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002 Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack) Source: International Congress 2017 – Medical education, web and internet Year: 2017 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021